Condition
Glucose Metabolism Disorders
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 104 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownMETabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)NCT07699380 · 2026-09-01
RECRUITINGA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307 · 2026-07-15
RECRUITINGInhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational DiabetesNCT06535789 · 2025-05-01
RECRUITINGClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUsNCT06674980 · 2024-12-20
RECRUITINGContinuous Glucose Monitoring Glycemic cHAracterization During PregnancyNCT06357728 · 2024-07-01
RECRUITINGRelationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy SubjectsNCT06051318 · 2024-06-06
RECRUITINGCognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 DiabetesNCT05543083 · 2023-06-02
RECRUITINGRare and Atypical Diabetes NetworkNCT05544266 · 2020-09-30
RECRUITINGRT-CGM in Young Adults at Risk of DKANCT04039763 · 2020-09-03
RECRUITINGRegulation of Endogenous Glucose Production by Central KATP ChannelsNCT03540758 · 2018-08-01
RECRUITINGSpecificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West IndiesNCT07576374 · 2026-06-01
NOT_YET_RECRUITINGThe CGM-OGTT Glycemic Homeostasis StudyNCT07288372 · 2025-12-18
NOT_YET_RECRUITINGFinancial Navigation and Peer Support to Improve Diabetes OutcomesNCT06619834 · 2025-02-11
COMPLETEDIn-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 DiabetesNCT06557317 · 2024-08-01
UNKNOWNHenagliflozin's Impact on Prediabetes RemissionNCT06448130 · 2024-06-01
NOT_YET_RECRUITINGEvaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese PatientNCT06145360 · 2023-12-01
COMPLETEDGroup Education Trial to Improve Transition for Parents of Adolescents With T1DNCT05445284 · 2023-10-10
COMPLETEDPredicting Dysglycemia in Individuals With Gestational Diabetes Immediately Postpartum Using Continuous Glucose MonitoringNCT04972955 · 2023-07-04
ACTIVE_NOT_RECRUITINGAnalysis of Volatile Organic Compounds in Patients With Type 1 Diabetes in Induced Hypoglycaemia With a Breath AnalyserNCT05933616 · 2023-04-20
COMPLETEDEfficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in ChinaNCT05726461 · 2023-02-11
UNKNOWNA Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 DiabetesNCT05691712 · 2023-02-05
COMPLETEDAn Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1DNCT05565248 · 2023-01-20
TERMINATEDBone Properties Following Exercise Induced Changes in Insulin Sensitivity in People With Type 2 DiabetesNCT06668090 · 2022-12-15
COMPLETEDDietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB StudyNCT05607745 · 2022-10-30
ACTIVE_NOT_RECRUITINGThe Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminNCT05505994 · 2022-09-28
UNKNOWNA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or BothNCT05260021 · 2022-04-13
COMPLETEDMetabolic Effects of Oral Sodium Butyrate Supplementation on Overweight IndividualsNCT06247020 · 2022-02-24
COMPLETEDDigital Foot Self-Management Program for Older-DiabetesNCT05272670 · 2022-02-15
UNKNOWNEnergy Metabolism and Acute Effects of Protein Diets in Metabolically Obese Normal Weight IndividualsNCT06802341 · 2022-02-01
ACTIVE_NOT_RECRUITINGAn Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1DNCT05210530 · 2022-01-24
COMPLETEDGlucose Homeostasis and Apple PolyphenolsNCT05951270 · 2022-01-14
TERMINATEDDifferent Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIITNCT05084079 · 2021-11-01
UNKNOWNSafety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II DiabetesNCT05014204 · 2021-10-29
COMPLETEDIntegrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)NCT05081037 · 2021-09-06
ACTIVE_NOT_RECRUITINGClosed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)NCT04902378 · 2021-06-15
COMPLETEDA Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 DiabetesNCT04809220 · 2021-04-13
COMPLETEDEffects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting GlucoseNCT04662866 · 2021-02-10
UNKNOWNEfficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic ControlNCT04529473 · 2021-02-03
COMPLETEDEfficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19NCT04371978 · 2020-10-01
TERMINATEDAssessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic SyndromeNCT04451616 · 2020-07-03
UNKNOWNAssessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With DiabetesNCT04485351 · 2020-07-01
UNKNOWNDevelopment of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management PlatformNCT04369833 · 2020-05-11
COMPLETEDEffect of Meal Texture on Glucose-metabolism and Gut Hormone Response After Bariatric SurgeryNCT04082923 · 2019-10-03
COMPLETEDThe Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 DiabetesNCT04098549 · 2019-09-12
COMPLETEDPhthalates Exposure in Type 2 Diabetic Patients and Diuretic TherapyNCT04242758 · 2019-06-04
UNKNOWNThe Influence of Overfeeding Different Macronutrients on Whole-body Insulin SensitivityNCT03863431 · 2019-05-22
UNKNOWNThe Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant RecipientsNCT03685773 · 2019-04-21
WITHDRAWNThe Effect of Water Intake on Glucose RegulationNCT03765008 · 2019-02-11
WITHDRAWNBisphenol A and Muscle Insulin SensitivityNCT03771066 · 2019-01-01
COMPLETEDDiabetes, Exercise and Liver Fat (DELIVER)NCT04004273 · 2018-10-30
COMPLETEDThe Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 DiabetesNCT03623113 · 2018-09-28
COMPLETEDEffects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 DiabetesNCT03623139 · 2018-09-28
COMPLETEDAzithromycin Insulin Diet Intervention Trial in Type 1 DiabetesNCT03682640 · 2018-09-01
UNKNOWNEffects on Glucose Homeostasis of Changes in Plasma Lipoproteins Induced by Nutritional and Pharmacologic StrategiesNCT05213988 · 2018-07-30
UNKNOWNEffects of Simulated Passive Jogging Device on Glucose Homeostasis, Muscle Strength and EnduranceNCT03550105 · 2018-06-05
COMPLETEDSoluble Epoxide Hydrolase Inhibition and Insulin ResistanceNCT03486223 · 2018-05-17
COMPLETEDLow-intensity Exercise in Metabolic SyndromeNCT04346836 · 2018-05-06
COMPLETEDDietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.NCT03889236 · 2018-05-03
COMPLETEDInvestigating Genetic Risk for Type 1 DiabetesNCT03503747 · 2018-04-25
COMPLETEDDiamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 DiabetesNCT03345004 · 2017-12-20
COMPLETEDCommon interventions
PlaceboDRUG11PlaceboDIETARY_SUPPLEMENT7DiazoxideDRUG3PF-04991532DRUG3AcarboseDRUG2ExerciseBEHAVIORAL2MetforminDRUG2Nicotinic acidDRUG2PioglitazoneDRUG21H-magnetic resonance spectroscopyOTHER16-DIGDRUG1A digital foot self-management programBEHAVIORAL1ABC-ACC interventionBEHAVIORAL1Advice Plus Lifestyle InterventionBEHAVIORAL1Aliskiren 150 mg (ALI 150)DRUG1Aliskiren 300 mg (ALI 300)DRUG1AM/Double - DFUOTHER1AM/Double - VLUOTHER1AM/Single - DFUOTHER1AM/Single - VLUOTHER1AMX0035DRUG1AndroidAPS-rt-CGM;DEVICE1Animal protein dietOTHER1AnthocyaninsDIETARY_SUPPLEMENT1Apple PolyphenolsDIETARY_SUPPLEMENT1
Leading sponsors
Pfizer
5
Eli Lilly and Company
4
University of Cambridge
4
Steno Diabetes Center Copenhagen
3
Albert Einstein College of Medicine
2
CRISPR Therapeutics AG
2
Jaeb Center for Health Research
2
KK Women's and Children's Hospital
2
Singapore Institute of Food and Biotechnology Innovation
2
Sun Yat-sen University
2
University of Eastern Finland
2
University of Pisa
2
Vanderbilt University Medical Center
2
Aarhus University Hospital
1
Arizona State University
1
Trial status mix
COMPLETED59
UNKNOWN19
RECRUITING10
ACTIVE_NOT_RECRUITING6
TERMINATED5
NOT_YET_RECRUITING3
WITHDRAWN2
Phase mix
NA50
PHASE212
PHASE310
PHASE19
PHASE48
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.